Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults 65 Years of Age
-
- STATUS
- Recruiting
-
- End date
- Jun 18, 2021
-
- participants needed
- 1780
-
- sponsor
- Pfizer
Updated on 16 December 2020
Pfizer CT.gov Call Center
Primary Contact
Diablo Clinical Research, Inc. (4.7 mi away) Contact
+71 other locationpneumococcal conjugate
vaccination
trivalent influenza vaccine
conjugate vaccine
pneumococcal vaccine
Summary
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Details
| Treatment | Saline, Influenza vaccine, Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) |
|---|---|
| Clinical Study Identifier | NCT04526574 |
| Sponsor | Pfizer |
| Last Modified on | 16 December 2020 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
pneumococcal conjugate
vaccination
trivalent influenza vaccine
conjugate vaccine
pneumococcal vaccine
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer